Director and 10% Owner Sells $489K in Atara Biotherapeutics Stock
summarizeResumen
The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.
check_boxEventos clave
-
Insider Sale
James Huang, a Director and 10% owner, disposed of 80,554 shares of Atara Biotherapeutics common stock.
-
Significant Value
The sale amounted to $489,019, a substantial transaction for the company.
-
Transaction Price
Shares were sold at a weighted average price of $6.07 on January 12, 2026, compared to the current stock price of $4.58.
auto_awesomeAnalisis
The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.
En el momento de esta presentación, ATRA cotizaba a 4,58 $ en NASDAQ dentro del sector Life Sciences, con una capitalización de mercado de aproximadamente 32,2 M$. El rango de cotización de 52 semanas fue de 4,25 $ a 19,15 $. Este documento fue evaluado con un sentimiento de mercado negativo y una puntuación de importancia de 8 sobre 10.